Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 12/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18216593 | 0.85 | KCNJ1 (0.54) | KCNJ1EGLN1MAPTKCNH2 | |
| SCHEMBL16906421 | 0.83 | KCNJ1 (0.58) | KCNJ1POLBBLMTDP1MAPT | |
| SCHEMBL14075471 | 0.81 | KCNJ1 (0.50) | KCNJ1EGLN1MAPTKCNH2 | |
| SCHEMBL16897518 | 0.80 | KCNJ1 (0.58) | KCNJ1MAPTKCNH2NOTUM | |
| SCHEMBL16869148 | 0.80 | KCNJ1 (0.58) | KCNJ1POLBBLMTDP1MAPT | |
| SCHEMBL15018359 | 0.79 | KCNJ1 (0.61) | KCNJ1MAPTKCNH2 | |
| SCHEMBL2731445 | 0.77 | KCNJ1 (0.68) | KCNJ1KCNH2 | |
| SCHEMBL2730624 | 0.77 | KCNJ1 (0.55) | KCNJ1MAPTKCNH2 | |
| SCHEMBL16101269 | 0.76 | KCNJ1 (0.57) | KCNJ1KCNH2NOTUM | |
| SCHEMBL2729427 | 0.75 | KCNJ1 (0.58) | KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | KCNJ1 2434/4885EGLN1 1655/4885POLB 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.